Lantern Pharma
LTRN
10 hedge funds and large institutions have $1.6M invested in Lantern Pharma in 2020 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 5 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
1.24% less ownership
Funds ownership: 2.57% → 1.33% (-1.2%)
17% less funds holding
Funds holding: 12 → 10 (-2)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
47% less capital invested
Capital invested by funds: $3.02M → $1.6M (-$1.42M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$113K |
| 2 |
IAIM
International Assets Investment Management
Orlando,
Florida
|
+$15.5K |
| 3 |
MFIM
Mesirow Financial Investment Management
Chicago,
Illinois
|
+$8.08K |
| 4 |
BlackRock
New York
|
+$4.01K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$985 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ZCA
Zeke Capital Advisors
Berwyn,
Pennsylvania
|
-$1.6M |
| 2 |
VC
Voss Capital
Houston,
Texas
|
-$158K |
| 3 |
CCM
Chiron Capital Management
Tallahassee,
Florida
|
-$9K |
| 4 |
RCG
Rock Creek Group
Washington,
District of Columbia
|
-$6.91K |
| 5 |
US Bancorp
Minneapolis,
Minnesota
|
-$4K |
LTRN Hedge Fund Activity: Q4 2020 in Review
10 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Lantern Pharma (LTRN) for Q4 2020, worth a combined $1.6M — down 47% from $3.02M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of LTRN and 3 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 3 added.
The largest buyer was Morgan Stanley, adding an estimated $113K. The largest seller was Zeke Capital Advisors, exiting entirely with an estimated $1.6M sold.
- 10 institutional investors held Lantern Pharma (LTRN) as of Q4 2020, down from 12 in Q3 2020.
- Funds reported $1.6M of Lantern Pharma stock for Q4 2020, down 47% quarter-over-quarter.
- 3 funds opened new Lantern Pharma positions in Q4 2020 and 5 closed out, a net change of -2 holders.
- The largest Lantern Pharma buyer in Q4 2020 was Morgan Stanley, an estimated $113K added.
- The largest Lantern Pharma seller in Q4 2020 was Zeke Capital Advisors, an estimated $1.6M sold.
Based on aggregated 13F filings for Q4 2020.